Alfonso Berrocal

3.4k total citations
60 papers, 681 citations indexed

About

Alfonso Berrocal is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alfonso Berrocal has authored 60 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 17 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alfonso Berrocal's work include Melanoma and MAPK Pathways (14 papers), CAR-T cell therapy research (14 papers) and Cutaneous Melanoma Detection and Management (13 papers). Alfonso Berrocal is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), CAR-T cell therapy research (14 papers) and Cutaneous Melanoma Detection and Management (13 papers). Alfonso Berrocal collaborates with scholars based in Spain, United States and Canada. Alfonso Berrocal's co-authors include Susana Puig, Salvador Martín‐Algarra, Enrique Espinosa, Iván Márquez‐Rodas, María González‐Cao, Ainara Soria, Luis de la Cruz‐Merino, Pablo Cerezuela, Ana Arance and José A. López-Martín and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Annals of Oncology.

In The Last Decade

Alfonso Berrocal

54 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alfonso Berrocal Spain 17 399 213 123 115 97 60 681
Leonard Christopher Schmeel Germany 16 237 0.6× 130 0.6× 120 1.0× 154 1.3× 140 1.4× 67 816
Carla M. van Herpen Netherlands 14 325 0.8× 195 0.9× 146 1.2× 113 1.0× 55 0.6× 27 608
Daniela Stramazzotti Italy 16 268 0.7× 197 0.9× 188 1.5× 203 1.8× 83 0.9× 43 894
Christopher Angel Australia 13 363 0.9× 269 1.3× 94 0.8× 74 0.6× 60 0.6× 31 663
Silvia Varricchio Italy 16 205 0.5× 215 1.0× 59 0.5× 59 0.5× 87 0.9× 60 682
Yabing Cao China 15 350 0.9× 191 0.9× 135 1.1× 144 1.3× 189 1.9× 52 811
Jamel Daoud Tunisia 22 540 1.4× 472 2.2× 190 1.5× 96 0.8× 99 1.0× 71 1.2k
B. Vasseur France 12 522 1.3× 149 0.7× 122 1.0× 129 1.1× 112 1.2× 34 887
Marie Alt France 11 543 1.4× 123 0.6× 256 2.1× 148 1.3× 38 0.4× 20 748
Giuseppina Della Vittoria Scarpati Italy 15 407 1.0× 438 2.1× 172 1.4× 116 1.0× 60 0.6× 44 973

Countries citing papers authored by Alfonso Berrocal

Since Specialization
Citations

This map shows the geographic impact of Alfonso Berrocal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Berrocal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Berrocal more than expected).

Fields of papers citing papers by Alfonso Berrocal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfonso Berrocal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Berrocal. The network helps show where Alfonso Berrocal may publish in the future.

Co-authorship network of co-authors of Alfonso Berrocal

This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Berrocal. A scholar is included among the top collaborators of Alfonso Berrocal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Berrocal. Alfonso Berrocal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583. 3 indexed citations
2.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391. 1 indexed citations
3.
Mortier, Laurent, Lisa Villabona, Ben Lawrence, et al.. (2024). Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. American Journal of Clinical Dermatology. 25(6). 987–996. 3 indexed citations
4.
5.
Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2020). LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Annals of Oncology. 31. S1173–S1173. 19 indexed citations
6.
Rodriguez, J.M. Piulats, Shreyaskumar Patel, Enrique Espinosa, et al.. (2020). 1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials. Annals of Oncology. 31. S764–S764. 3 indexed citations
7.
Márquez‐Rodas, Iván, et al.. (2019). A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain. Clinical & Translational Oncology. 21(12). 1754–1762. 1 indexed citations
8.
Soria, Ainara, et al.. (2019). PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN. Value in Health. 22. S457–S457. 1 indexed citations
9.
García‐Carbonero, Rocio, Iván Márquez‐Rodas, Luis de la Cruz‐Merino, et al.. (2019). Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. The Oncologist. 24(10). 1375–1383. 19 indexed citations
10.
Arance, Ana, Alfonso Berrocal, José A. López-Martín, et al.. (2016). Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience. Clinical & Translational Oncology. 18(11). 1147–1157. 17 indexed citations
11.
Berrocal, Alfonso, Ana Arance, Enrique Espinosa, et al.. (2015). SEOM guidelines for the management of Malignant Melanoma 2015. Clinical & Translational Oncology. 17(12). 1030–1035. 7 indexed citations
12.
Puig, Susana & Alfonso Berrocal. (2015). Management of high-risk and advanced basal cell carcinoma. Clinical & Translational Oncology. 17(7). 497–503. 66 indexed citations
13.
Berrocal, Alfonso, Enrique Espinosa, Ricardo Fernández‐de‐Misa, et al.. (2014). Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in Therapy. 31(9). 945–960. 30 indexed citations
14.
Gallego, Óscar, Míriam Cuatrecasas, Manuel Benavides, et al.. (2013). Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. Journal of Neuro-Oncology. 116(2). 413–419. 31 indexed citations
15.
Berrocal, Alfonso, Miguel Gil Gil, Óscar Gallego, et al.. (2012). SEOM guideline for the treatment of malignant glioma. Clinical & Translational Oncology. 14(7). 545–550. 5 indexed citations
16.
Camps, Carlos, Vega Iranzo, Cristina Caballero, et al.. (2011). Oncology outside hospital: a new experience for the benefit of longer survivors. Clinical & Translational Oncology. 13(4). 249–253. 4 indexed citations
17.
Iranzo, Vega, Rafael Sirera, Roy M. Bremnes, et al.. (2011). Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer. 12(4). 224–230. 15 indexed citations
18.
Camps, Carlos, Rafael Sirera, Roy M. Bremnes, et al.. (2006). Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer. 52(3). 343–347. 22 indexed citations
19.
Camps, Carlos, Catalina Vadell, Ramón García Gómez, et al.. (2000). Quimioterapia de combinación cisplatino y vinorelbina en carcinoma no microcítico pulmonar (NSCLC) inoperable: un ensayo fase II multicéntrico. Clinical & Translational Oncology. 2(2). 84–90. 1 indexed citations
20.
Berrocal, Alfonso, et al.. (1989). POPULATION PHARMACOKINETIC STUDY OF GENTAMICIN AND A BAYESIAN APPROACH IN PATIENTS WITH RENAL IMPAIRMENT. Journal of Clinical Pharmacy and Therapeutics. 14(3). 213–223. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard Christopher Schmeel Breakdown of academic impact, for papers by Carla M. van Herpen Breakdown of academic impact, for papers by Daniela Stramazzotti Breakdown of academic impact, for papers by Christopher Angel Breakdown of academic impact, for papers by Silvia Varricchio Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by Jamel Daoud Breakdown of academic impact, for papers by B. Vasseur Breakdown of academic impact, for papers by Marie Alt Breakdown of academic impact, for papers by Giuseppina Della Vittoria Scarpati
Rankless by CCL
2026